Heterogeneity in the responses of human lung mast cells to stem cell factor

Clinical and Experimental Allergy

Volumn 43, Issue 1, 2013, Pages 50-59

  Lewis, A ^a   Wan, J ^a   Baothman, B ^b   Monk, P N ^a   Suvarna, S K ^b   Peachell, P T ^a,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

C kit; CD63; Cysteinyl leukotrienes; Dasatinib; Histamine; Human lung mast cell; Imatinib; Nilotinib; Prostaglandin D2; Stem cell factor

Indexed keywords

CD63 ANTIGEN; DASATINIB; HISTAMINE; IMATINIB; IMMUNOGLOBULIN E; NILOTINIB; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN D2; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ARTICLE; CELL ISOLATION; CONTROLLED STUDY; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG; MAST CELL; MEDIATOR RELEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

FEMALE; FLOW CYTOMETRY; HISTAMINE RELEASE; HUMANS; IMMUNOGLOBULIN E; LUNG; MALE; MAST CELLS; PROSTAGLANDIN D2; STEM CELL FACTOR;

EID: 84871684115     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12045     Document Type: Article

References (41)

1. Holgate ST, Hardy C, Robinson C, Agius RM, Howarth PH. The mast cell as a primary effector cell in the pathogenesis of asthma. J Allergy Clin Immunol 1986; 77:274-82.
2. Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res 2006; 34:97-115.
3. Jensen BM, Akin C, Gilfillan AM. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br J Pharmacol 2008; 154:1572-82.
4. Akin C, Metcalfe DD. The biology of kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 2004; 114:13-19.
5. T type of human lung mast cell. J Allergy Clin Immunol 2005; 115:1162-8.
6. Bischoff SC, Dahinden CA. c-kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med 1992; 175:237-44.
7. Takaisha T, Morita Y, Hirai K et al. Effect of cytokines on mediator release from human dispersed lung mast cells. Allergy 1994; 49:837-42.
8. Hundley TR, Gilfillan AM, Tkaczyk C, Andrade MV, Metcalfe DD, Beaven MA. Kit and FcεRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. Blood 2004; 104:2410-17.
9. Bachelet I, Levi-Schaffer F. Mast cells as effector cells: a co-stimulating question. Trends Immunol Sci 2007; 28:360-5.
10. Bingham CO, Austen KF. Mast-cell responses in the development of asthma. J Allergy Clin Immunol 2000; 105:S527-34.
11. Robinson DS. The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle? J Allergy Clin Immunol 2004; 114:58-65.
12. Kobayashi H, Ishizuka T, Okayama Y. Human mast cells and basophils as sources of cytokines. Clin Exp Allergy 2000; 30:1205-12.
13. Baghestanian M, Hofbauer R, Kiener HP et al. The c-kit ligand stem cell factor and anti-IgE promote expression of monocyte chemoattractant protein-1 in human lung mast cells. Blood 1997; 90:4438-49.
14. Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003; 111:S18-S36.
15. Elias JA, Zhou Z, Chupp G, Homer RJ. Airway remodeling in asthma. J Clin Invest 1999; 104:1001-6.
16. Bradding P, Walls AF, Holgate ST. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006; 117:1277-84.
17. Al-Muhsen SZ, Shablovsky G, Olivenstein R, Mazer B, Hamid Q. The expression of stem cell factor and c-kit receptor in human asthmatic airways. Clin Exp Allergy 2004; 34:911-16.
18. Da Silva CA, de Blay F, Israel-Biet D et al. Effect of glucocorticoids on stem cell factor expression in human asthmatic bronchi. Clin Exp Allergy 2006; 36:317-24.
19. Ali H, Pearce FL. Isolation and properties of cardiac and other mast cells from the rat and guinea-pig. Agents Actions 1985; 16:138-40.
20. Gilbert HS, Ornstein L. Basophil counting with a new staining method using alcian blue. Blood 1975; 46:279-86.
21. Weston MC, Anderson N, Peachell PT. Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function. Br J Pharmacol 1997; 121:287-95.
22. Havard S, Scola A-M, Kay LJ, Ishmael SS, MacGlashan DW, Peachell PT. Characterization of syk expression in human lung mast cells: relationship with function. Clin Exp Allergy 2011; 41:378-88.
23. Ennis M. Current techniques of histamine determination: automated fluorometric assays. Handbook of Exp Pharmacol 1991; 97:31-8.
24. Siraganian RP. An automated continuous-flow system for the extraction and fluorometric analysis of histamine. Anal Biochem 1974; 57:383-94.
25. Schäfer T, Starkl P, Allard C, Wolf RM, Schweighoffer T. A granular variant of CD63 is a regulator of repeated human mast cell degranulation. Allergy 2010; 65:1242-55.
26. MacGlashan D. Expression of CD203c and CD63 in human basophils: relationship to differential regulation of piecemeal and anaphylactic degranulation processes. Clin Exp Allergy 2010; 40:1365-77.
27. Amano T, Furuno T, Hirashima N, Ohyama N, Nakanishi M. Dynamics of intracellular granules with CD63-GFP in rat basophilic leukemia cells. J Biochem 2001; 129:739-44.
28. Fleming TJ, Donnadieu E, Song CH, Van Laethen F, Galli SJ, Kinet J-P. Negative regulation of FcεRI-mediated degranulation by CD81. J Exp Med 1997; 186:1307-14.
29. Peng WM, Yu CF, Kolanus W et al. Tetraspanins CD9 and CD81 are molecular partners of trimeric FcεRI on human antigen-presenting cells. Allergy 2011; 66:605-11.
30. Lukacs NW, Kunkel SL, Strieter RM et al. The role of stem cell factor (c-kit ligand) and inflammatory cytokines in pulmonary mast cell activation. Blood 1996; 87:2262-8.
31. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 2006; 533:327-40.
32. 2-adrenoceptor function in human mast cells by stem cell factor. J Allergy Clin Immunol 2010; 125:257-63.
33. 2 in vivo. Thorax 2004; 59:453-5.
34. Balzar S, Fajt ML, Comhair SAA et al. Mast cell phenotype, location, and activation in severe asthma. Am J Respir Crit Care Med 2011; 183:299-309.
35. Schulman ES, Kagey-Sobotka A, MacGlashan DW et al. Heterogeneity of human mast cells. J Immunol 1983; 131:1936-41.
36. Jensen BM, Beaven MA, Iwaki S, Metcalfe DD, Gilfillan AM. Concurrent inhibition of Kit- and FcεRI-mediated signalling: coordinated suppression of mast cell activation. J Pharmacol Exp Ther 2008; 324:128-38.
37. Kneidinger M, Schmidt U, Rix U et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood 2008; 111:3097-107.
38. El-Agamy DS. Anti-allergic effects of nilotinib on mast cell-mediated anaphylaxis like reactions. Eur J Pharmacol 2012; 680:115-21.
39. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305:399-401.
40. Hantschel O, Rix U, Schmidt U et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007; 104:13283-8.
41. Royer B, Varadaradjalou S, Saas P, Guillosson JJ, Kantelip JP, Arock M. Inhibition of IgE-induced activation of human mast cells by IL-10. Clin Exp Allergy 2001; 31:694-704.